The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)—Exploration of germline DDR alteration landscape and potential associations with antitumor activity.
 
Tanya B. Dorff
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Bayer; Bristol-Myers Squibb; Dendreon; Exelixis; Janssen Oncology; Noxopharm; Seagen
Research Funding - Pfizer (Inst)
 
Karim Fizazi
Honoraria - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer; Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Curevac; ESSA (Inst); Janssen Oncology (Inst); Orion; Sanofi (Inst)
Travel, Accommodations, Expenses - Janssen; MSD
 
Douglas Laird
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer (Inst)
 
Philippe Barthélémy
Honoraria - Astellas Pharma; BMS; IPSEN; Janssen-Cilag; Merck KGaA; MSD; Novartis; Pfizer
Consulting or Advisory Role - Amgen; AstraZeneca; BMS; Eisai; ipsen; Janssen-Cilag; Merck KGaA; MSD Oncology; Pfizer
Travel, Accommodations, Expenses - Astellas Pharma; BMS; IPSEN; Janssen-Cilag; MSD; Pfizer
 
Remy Delva
No Relationships to Disclose
 
Marco Maruzzo
No Relationships to Disclose
 
Adam Stirling
Honoraria - AstraZeneca (Inst); Pfizer (Inst)
 
Jean-Pascal H. Machiels
Consulting or Advisory Role - ALX Oncology; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; CUE Biopharma; eTHERNA; Incyte; Innate Pharma; ITeos Therapeutics; Janssen; Merck Serono; Merck Sharp & Dohme; NEKTAR; Novartis; Pfizer; Roche
Research Funding - Bayer; Janssen; Novartis; Sanofi
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; Pfizer
Other Relationship - PsiOxus Therapeutics
 
Herlinde Dumez
Travel, Accommodations, Expenses - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Ipsen (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
 
Vincent Renard
Travel, Accommodations, Expenses - AstraZeneca (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
 
Julia Hopkins
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Lee A. Albacker
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Hsiang-Chun Chen
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer (Inst)
 
Cynthia G. Healy
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer (Inst)
 
Jijumon Chelliserry
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer (Inst)
 
Inge M. van Oort
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen; MSD/AstraZeneca; Roche; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst)
 
Giorgio V. Scagliotti
Honoraria - AstraZeneca; Johnson & Johnson/Janssen; Lilly; MSD Oncology; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; BeiGene; Lilly
Speakers' Bureau - AstraZeneca; beigene; Roche
Travel, Accommodations, Expenses - Bayer
 
Johann S. De Bono
Employment - Institute of Cancer Research
Honoraria - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; BioExcel; Boehringer Ingelheim; Celgene; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Medivation; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
Consulting or Advisory Role - Amgen; Astellas Pharma; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
Research Funding - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; CellCentric; Daiichi Sankyo; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Vertex
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Cellcentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
 
Niven Mehra
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen-Cilag; MSD Oncology (Inst)
Research Funding - Astellas Pharma (Inst); Janssen-Cilag (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Janssen-Cilag; MSD Oncology; Roche